The direct reductive amination of 2,5-diformylfuran (DFF) with ammonia to 2,5-bis(aminomethyl)furan (BAF) was demonstrated, for the first time, over the commercial type Nickel-Raney and acid treated Nickel-Raney catal...The direct reductive amination of 2,5-diformylfuran (DFF) with ammonia to 2,5-bis(aminomethyl)furan (BAF) was demonstrated, for the first time, over the commercial type Nickel-Raney and acid treated Nickel-Raney catalysts. The effects of reaction parameters such as reaction medium, temperature and hydrogen pressure were described. The acid treated Nickel-Raney catalyst exhibited the highest BAF yield in the THF-water mixed reaction medium. The relatively higher Ni0 species composition and larger surface area of the acid treated Nickel-Raney catalyst with specific reaction conditions contributed greatly to the BAF formation. The oligomeric species, such as furanic imine trimers and tetramers confirmed by MALDI-MS analysis were presented as the intermediates of DFF reductive amination.展开更多
Tissue inhibitors of metalloproteases(TIMPs)have caught the attention of many scientists due to their role in various physiological and pathological processes.TIMP-1,2,3,and 4 are known members of the TIMPs family.TIM...Tissue inhibitors of metalloproteases(TIMPs)have caught the attention of many scientists due to their role in various physiological and pathological processes.TIMP-1,2,3,and 4 are known members of the TIMPs family.TIMPs exert their biological effects by,but are not limited to,inhibiting the activity of metalloproteases(MMPs).The balance between MMPs and TIMPs is critical for maintaining homeostasis of the extracellular matrix(ECM),while the imbalance between MMPs and TIMPs can lead to pathological changes,such as cancer.In this re-view,we summarized the current knowledge of TIMP-1 in several pulmonary diseases namely,acute lung injury(ALI)/acute respiratory distress syndrome(ARDS),pneumonia,asthma,chronic obstructive pulmonary disease(COPD),cystic fibrosis,and pulmonary fibrosis.Considering the potential of TIMP-1 serving as a non-invasive di-agnostic and/or prognostic biomarker,we also reviewed the circulating TIMP-1 levels in translational and clinical studies.展开更多
文摘The direct reductive amination of 2,5-diformylfuran (DFF) with ammonia to 2,5-bis(aminomethyl)furan (BAF) was demonstrated, for the first time, over the commercial type Nickel-Raney and acid treated Nickel-Raney catalysts. The effects of reaction parameters such as reaction medium, temperature and hydrogen pressure were described. The acid treated Nickel-Raney catalyst exhibited the highest BAF yield in the THF-water mixed reaction medium. The relatively higher Ni0 species composition and larger surface area of the acid treated Nickel-Raney catalyst with specific reaction conditions contributed greatly to the BAF formation. The oligomeric species, such as furanic imine trimers and tetramers confirmed by MALDI-MS analysis were presented as the intermediates of DFF reductive amination.
基金The Genotype-Tissue Expression(GTEx)Project was supported by the Common Fund of the Office of the Director of the National Insti-tutes of Health(NIH),and by National Cancer Institute(NCI),National Human Genome Research Institute(NHGRI),National Heart,Lung,and Blood Institute(NHLBI),National Institute on Drug Abuse(NIDA),Na-tional Institute of Mental Health(NIMH),and National Institute of Neu-rological Disorders and Stroke(NINDS).The data used for the analyses described in Fig.1 A were obtained from the GTEx Portal of The Human Protein Atlas on 02/28/2023.
文摘Tissue inhibitors of metalloproteases(TIMPs)have caught the attention of many scientists due to their role in various physiological and pathological processes.TIMP-1,2,3,and 4 are known members of the TIMPs family.TIMPs exert their biological effects by,but are not limited to,inhibiting the activity of metalloproteases(MMPs).The balance between MMPs and TIMPs is critical for maintaining homeostasis of the extracellular matrix(ECM),while the imbalance between MMPs and TIMPs can lead to pathological changes,such as cancer.In this re-view,we summarized the current knowledge of TIMP-1 in several pulmonary diseases namely,acute lung injury(ALI)/acute respiratory distress syndrome(ARDS),pneumonia,asthma,chronic obstructive pulmonary disease(COPD),cystic fibrosis,and pulmonary fibrosis.Considering the potential of TIMP-1 serving as a non-invasive di-agnostic and/or prognostic biomarker,we also reviewed the circulating TIMP-1 levels in translational and clinical studies.